A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT01489943
• Date of registration: 01/12/2011
• Prospective Registration: No
• Primary sponsor: GlaxoSmithKline
• Public title: A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects
• Scientific title: A Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects
• Date of first enrolment: September 19, 2011
• Target sample size: 24
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT01489943
• Study type: Interventional
• Study design: Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1

Countries of recruitment

United States

Contacts

• Name: GSK Clinical Trials
• Affiliation: GlaxoSmithKline

Key inclusion & exclusion criteria

Inclusion Criteria:

- Aspartate transaminase, alanine transaminase, alkaline phosphatase and bilirubin less
than or equal to 1.5x the upper limit of normal (isolated bilirubin >1.5x the upper
limit of normal is acceptable if bilirubin is fractionated and direct bilirubin <35%).

- Healthy as determined by a responsible and experienced physician, based on a medical
evaluation including medical history, physical examination, laboratory tests and
cardiac monitoring. A subject with a clinical abnormality or laboratory parameters
outside the reference range for the population being studied may be included only if
in the opinion of the Investigator the finding is unlikely to introduce additional
risk factors and will not interfere with the study procedures.

- Male or female between 18 and 55 years of age inclusive, at the time of signing the
informed consent.

- A female subject is eligible to participate if she is of; non-childbearing potential
defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or
postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a
blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and
estradiol < 40 pg/ml (<147 pmol/L) is confirmatory].

- Body weight more than or equal to 60 kg and BMI within the range 19 - 30 kg/m2
(inclusive).

- Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form (including participation in
pharmacogenetics research).

- QTc < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.

Exclusion Criteria:

- A positive pre-study Hepatitis B surface antigen or Hepatitis B core antibody or
positive Hepatitis C antibody result within 3 months of screening

- Current illness or disability that may affect the interpretation of clinical data, or
otherwise contraindicates participation in this clinical study (e.g., an unstable
cardiovascular, autoimmune, renal, hepatic, pulmonary, endocrine, metabolic,
gastrointestinal, haematologic, or neurological condition or mental impairment)

- Current or pre-existing condition interfering with normal gastrointestinal anatomy or
motility, hepatic or renal function, that could interfere with the absorption,
metabolism, or excretion of the study drugs; including but not limited to liver
disease and known hepatic or biliary abnormalities (with the exception of Gilbert's
syndrome or asymptomatic gallstones).

- A positive pre-study drug/alcohol screen.

- A positive test for HIV antibody.

- History of regular alcohol consumption within 6 months of the study defined as an
average weekly intake of >14 drinks for males or >7 drinks for females. One drink is
equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine
or 1.5 ounces (45 ml) of 80 proof distilled spirits.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.

- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
supplements (including St John's Wort [Hypericum perforatum], kava, ephedra [ma
huang], gingko biloba, DHEA, vohimbe, saw palmetto, panaz ginseng, red yeast rice)
within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives
(whichever is longer) prior to the first dose of study medication and through the
duration of the study, unless in the opinion of the Investigator and GSK Medical
Monitor the medication will not interfere with the study procedures or compromise
subject safety. Herbal medications include, but are not limited to: traditional
Chinese, Korean and Japanese medicines, Panaz ginseng, Gingko biloba or St John's wort
(Hypericum perforatum) or any Traditional Chinese herbal medicines (TCM) South Asian
Ayurvedic medicine, Traditional Korean Medicines and Japanese Kampo.

- Use of aspirin, aspirin-containing compounds, salicylates or nonsteroidal
anti-inflammatory drugs (NSAIDs) within 48 hours of the first dose and is unwilling to
abstain from use of these medications until the last pharmacokinetic sample has been
collected.

- Use of liquid antacids (e.g. Maalox, Mylanta, Amphogel, milk of magnesia) or tablets
(including chewable) antacids (e.g. TUMS™) within 48 hours of the first dose and is
unwilling to abstain from use of these medications until the last dose of study
medication.

- Use of digoxin or related cardiac glycoside (e.g digitoxin, deslanoside, lanatoside C,
metildigoxin) within 7 days prior to screening and throughout the study.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or GSK
Medical Monitor, contraindicates their participation.

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.

- Pregnant females as determined by positive serum hCG test at screening or prior to
dosing.

- Lactating females.

- Unwillingness or inability to follow the procedures outlined in the protocol.

- Subject is mentally or legally incapacitated.

- History of sensitivity to heparin or heparin-induced thrombocytopenia.

- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or
nicotine-containing products within 6 months prior to screening. This includes chewing
tobacco, Gutka, hand-rolled tobacco cigarettes, Biddis, cigars, and Snuff.

- Use of caffeine- or theobromine-containing beverages (e.g., coffee, tea, certain
colas, green tea and oolong tea, Yerba Mate, Guarana, and South American cocoa) and
foods (e.g., chocolate), or alcohol-containing beverages within 72 hours prior to
dosing

- Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos,
exotic citrus fruits, grapefruit hybrids, fruit juice blends, apple or orange juice,
vegetables from the mustard green family [e.g., kale, broccoli, watercress, collard
greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats from 7 days prior



Age minimum: 18 Years
Age maximum: 55 Years
Gender: All

Health Condition(s) or Problem(s) studied

Crohn's Disease

Intervention(s)

Drug: Omeprazole 40 mg

Drug: Pioglitazone 15 mg

Drug: Rosuvastatin 10 mg

Drug: GSK1605786 500 mg

Drug: Midazolam 3 mg

Primary Outcome(s)

To investigate the potential of GSK1605786 to inhibit or induce drug metabolism via various CYP enzymes [Time Frame: 16 Days]

To investigate the potential of GSK1605786 to inhibit the BCRP and/or OATP1B1 transporters [Time Frame: 16 Days]

Secondary Outcome(s)

To determine the exposure of two metabolites, GSK2635622 (CCX062) and GSK2656694 (CCX304), relative to GSK1605786 (parent compound) following single and repeat administration of GSK1605786. [Time Frame: 16 Days]

To assess the safety and tolerablity of repeat oral doses of GSK1605786 [Time Frame: 21 Days]

Secondary ID(s)

114671

Source(s) of Monetary Support

Please refer to primary and secondary sponsors